PF-Atlas › Clinical Trials › NCT07929948

A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis

ND-003 Tablets · Phase 2

Registry ID
NCT07929948
Phase
Phase 2
Status
Enrolling by invitation
Drug / intervention
ND-003 Tablets
Sponsor
Shenzhen NewDEL Biotech, Co., Ltd
Enrollment
10
Locations
1

About this trial

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease that predominantly affects middle-aged and older adults. Progressive replacement of normal lung parenchyma by extracellular matrix and destruction of the alveolar architecture lead to reduced lung compliance and impaired gas exchange. Clinically, IPF is characterized by progressively worsening dyspnea, restrictive ventilatory impairment, impaired gas exchange, hypoxemia, and, in advanced cases, respiratory failure. Current pharmacological treatment of IPF is primarily based on antifibrotic therapy. Pirfenidone and nintedanib were the first two antifibrotic agents approved for IPF and have been shown to slow the decline in forced vital capacity (FVC) through different mechanisms of action. Pi

View NCT07929948 on ClinicalTrials.gov →

Medical disclaimer. This page summarizes public trial data for NCT07929948 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.